Results 61 to 70 of about 9,741 (153)
Platelets, 2017 Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS).
Rebecca Gosling +7 more
doaj +1 more source
Vascular Health and Risk Management, 2009 Nicholas B Norgard,1 Mazen Abu-Fadel21University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA; 2University of Oklahoma Health Sciences Center, Cardiovascular Section, Oklahoma City, OK, USAAbstract: Antiplatelet agents are
Nicholas B Norgard, Mazen Abu-Fadel
doaj
Clinical Medicine Insights: Cardiology, 2016 Objectives A growing body of clinical and laboratory evidence indicates that inflammation plays a crucial role in atherosclerosis. In the present study, we compared the effects of clopidogrel and prasugrel on high-sensitivity C-reactive protein (hs-CRP ...
Shokoufeh Hajsadeghi +9 more
doaj +1 more source
BMC Cardiovascular Disorders, 2018 Background Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied.
Pravesh Kumar Bundhun, Feng Huang
doaj +1 more source
Open Heart, 2019 Background There is a paucity of real-world outcome data comparing clopidogrel, prasugrel and ticagrelor in primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
Jim McLenachan +12 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Over the past decade, major society guidelines have recommended the use of newer P2Y12 inhibitors over clopidogrel for those undergoing percutaneous coronary intervention for acute coronary syndrome.
Mohamed O. Mohamed +9 more
doaj +1 more source
Acta Scientiarum. Health Sciences, 2014 Current study develops and validates a dissolution test for Prasugrel hydrochloride 10 mg in coated tablets. After sink condition, filters and drug stability were evaluated, the discriminatory dissolution conditions were achieved with a USP apparatus 1 ...
Camila Rigobello +2 more
doaj +1 more source
Frontiers in Cardiovascular MedicineBackgroundData are lacking on the effects of the alternation of P2Y12 receptor antagonists (P2Y12) on bleeding and outcome in patients with myocardial infarction (MI) with cardiogenic shock (CS). We compared the effects of different P2Y12 and alternation
Vojko Kanic, Gregor Kompara
doaj +1 more source
MCBS (Molecular and Cellular Biomedical Sciences)Background: In acute coronary syndrome (ACS), antiplatelet therapy is crucial for inhibiting platelet aggregation. Dual antiplatelet therapy (DAPT) commonly employs aspirin along with clopidogrel, prasugrel, or ticagrelor. This is well known that aspirin
Muhammad Naufal Hibatullah +2 more
doaj +1 more source
Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
MedicinesIntroduction: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. Purpose: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatelet ...
Fadel Bahouth +10 more
doaj +1 more source